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Abstract: 
Background: Acute cellular rejection (ACR) is a major complication in heart transplantation (HTx). 
Endomyocardial biopsy is the reference method for early detection of ACR, but a new non-invasive approach 
is needed. Tentative candidates could be circulating microRNAs. This study aimed to discover and validate 
microRNAs in serum for ACR detection after HTx. 
 
Methods: This prospective, observational, single-center study included 121 HTx patients. ACR was graded 
according to International Society of Heart and Lung Transplantation classification (0R−3R). First, in the 
discovery phase, microRNA expression profile was carried out in serum samples from patients at pre-
rejection, during, and post-rejection time (0RS1 → 2RS2 → 0RS3). Relative expression (2-ΔCq) of 179 
microRNAs per sample was analyzed by reverse transcription quantitative polymerase chain reaction. 
Second, a microRNA with a significant rise and fall pattern during ACR was selected for the next validation 
phase, where it was analyzed (reverse transcription quantitative polymerase chain reaction) in serum samples 
from 2 groups of patients: the no-ACR group (0R grade) and the ACR group (≥2R grade). Finally, a 
sensitivity analysis (receiver operating characteristic curve) was done to assess microRNA accuracy for ACR 
detection in HTx. 
 
Results: A total of 21 ACR episodes (0RS1 →  2RS2 → 0RS3) with their respective serum samples (n = 63) 
were included in the discovery phase. Among the 179 microRNAs analyzed, only miR-181a-5p met the rise 
and fall criteria. In the validation phase, miR-181a-5p relative expression (2-ΔCq) in the ACR group (n = 45) 
was significantly overexpressed (p < 0.0001) vs the no-ACR group (n = 45). miR-181a-5p showed an area 
under the curve of 0.804 (95% confidence interval: 0.707-0.880); sensitivity and specificity of 78% and 76%, 
respectively; and a negative predicted value of 98%. 
 
Conclusions: miR-185a-5p in serum is a candidate as a non-invasive ACR biomarker (area under the curve = 
0.80 and negative predicted value = 98%). Thus, this biomarker could reduce the need for endomyocardial 
biopsies and the associated risks and costs of this invasive procedure. 
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Heart transplantation (HTx) is the preferred option for patients with end-stage heart failure who 
are eligible. However, patients are at risk for developing several complications during the post-
transplant period.1 One of the most frequent complications is acute cellular rejection (ACR),1 an 
alloimmune response where T-cell activation plays a central role. In fact, up to 25% of patients 
will present any grade of ACR during the first year after transplantation, and a significant minority 
of these patients will require treatment.1 The gold standard method to detect ACR has been the 
endomyocardial biopsy (EMB), which is an invasive and uncomfortable procedure for the patients 
with the potential risk of serious complications.2 Moreover, the possibility of sampling error with 
false negative results, as well as a pathological grading system with substantial observer 
dependency,3 make EMB a technique with important limitations. 
 
Non-invasive methods4 (e.g., echocardiography, cardiac magnetic resonance imaging, and 
nuclear imaging) and the newest molecular techniques (e.g., gene expression5,6 and donor-derived 
cell-free DNA7) are being investigated to improve the diagnostic of ACR. In the last years, micro- 
RNAs have emerged as a potential biomarker.8,9 
 
MicroRNAs are small 21−25 single-stranded RNAs that regulate gene expression by binding to 
a complementary nucleotide sequence in messenger RNA.10 MicroRNAs possess many natural 
characteristics that make them excellent potential clinical biomarkers, as they are present in 
circulation and they are remarkably stable.8 Unique microRNA fingerprints that identify disease 
states ranging from cardiovascular disease to diabetes and cancer have been identified.9,11 In the 
field of HTx, at least 7 studies were performed trying to elucidate the possible role of microRNAs 
as ACR biomarkers (Table 1).12−18 Five studies analyzed the presence of circulating 
microRNAs,12,13,15−17 whereas the other 2 focus on the expression of microRNAs in EMB.14,18 
However, the low replicability observed between these studies, with 12 different microRNAs 
reported as potential ACR biomarkers (Table 1), has been the main reason why many promising 
microRNA biomarkers have never reached the clinical setting.19 A possible explanation for the 
poor reproducibility in these studies could be the microRNA biological variation, the different 
microRNA profiles studied, and a deficient analytic standardization.20 Thus, in recent years, 
numerous recommendations have been emerging to standardize the entire microRNA analytic 
process.20 Moreover, the biological variation could be minimized with an appropriate study 
design.21 These last considerations were carefully taken into account in this study that aimed to 
evaluate the potential of circulating microRNAs as biomarkers of ACR detection in HTx. 
Methods 
Study design 
This prospective, observational, single-center study included patients who underwent HTx 
between April 2013 and August 2018 in the Complexo Hospitalario Universitario A Coruña (A 
Coruña, Spain). The EMB protocol to monitor rejection was every 10 to 15 days in the first 2 
months, every 20 days in Months 3 and 4, and monthly in Months 5 and 6. After the sixth month, 
in stable patients and without any episode of treated rejection, the next EMB was at 12 months; in 
those patients who had an episode of rejection treated or needed to reduce immunosuppression 
because of complications, EMBs were performed every 2 months up to 12 months. On the same 
day, before the EMB procedure, blood samples were drawn to monitor laboratory parameters 
according to the standard clinical practice of the HTx program, and the remaining serum volume 
was aliquoted and sent to the research laboratory. EMBs were graded according to the 
International Society of Heart and Lung Transplantation 2005 criteria for ACR: no rejection, 0R; 
mild rejection, 1R; moderate rejection, 2R; and severe rejection, 3R.22 In this study, rejection was 
considered when EMB grade was ≥2R (because in asymptomatic patients without graft 
dysfunction, it is usually the threshold for rejection treatment) and no rejection when EMB grade 
was 0R. The study was approved by the local Ethics Committee (Comite ético de investigación de 
Galicia, reference: 2015/311). The standard immunosuppression protocol was triple therapy with 
tacrolimus, mycophenolate mofetil, and prednisone. Patients received induction therapy mostly 
with basiliximab and, in certain cases such as sensitized patients, thymoglobulin. Treatment of 
rejection episodes was with intravenous steroid bolus, 250 mg to 1,000 mg depending on severity, 
for 3 days. Written informed consent was obtained from all patients in accordance with the 
Declaration of Helsinki. 
 
The study was performed in 2 phases. First, in the discovery phase, a microRNA expression 
profile was carried out to identify and select circulating microRNAs differentially expressed 
during ACR. Then, a microRNA with a significant rise and fall pattern during ACR was included 
in the later validation phase to assess their diagnostic value to detect ACR in HTx patients. 
Discovery phase 
In the discovery phase, the patients included were those in whom a Grade ≥2R EMB and a 
previous and a subsequent Grade 0R EMB (not necessarily the one that preceded or followed the 
Grade ≥2R EMB, but the nearest ones) were reported. Serum samples matched in time with those 
EMBs were selected and called 0RS1 (pre-rejection), 2RS2 (rejection), and 0RS3 (post-rejection). 
The entire episode, named as 0RS1 → 2RS2 → 0RS3, and their 3 serum samples were always 
processed in the same run to minimize analytic variability. 
 
RNA was isolated from 200 µl of serum using miRNeasy Serum/Plasma Advanced Kit 
(Qiagen, Hilden, Germany). Total RNA was eluted in 21 µl of RNase-free water, and 
complementary DNA synthesis was performed following miRCURY LNA RT Kit (Qiagen) 
instructions. A total of 179 microRNAs per serum sample (Supplementary Table S1, available 
online at www.jhltonline.org) were analyzed with the quantitative polymerase chain reaction 
(qPCR) kit miRCURY LNA miRNA Serum/Plasma Focus PCR Panel Kit (Qiagen) in a 
LightCycler 480 Real-Time PCR System (Roche, Basel, Switzerland). Roche LC software was 
used for acquiring the quantification cycle (Cq) by the second derivative method. Detailed steps to 
perform RNA isolation, reverse transcription (RT), and qPCR are described in the Supplementary 
Material (available online).  
  
Table 1 MicroRNA Studies Associated with Cellular Rejection in Serum and/or Blood from Heart Transplantation Patients 
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AACR, after acute cellular rejection; ACR, acute cellular rejection; AMR, antibody-mediated rejection; AUC, area under the curve; BACR, before acute cellular rejection; DACR, during acute cellular rejection; NR, no rejection. 
A cut-off for unspecific amplification was set at Cq = 37. In the case of undetectable icroRNA, 
Cq was set to 37. Those micro-RNAs that were not detected in more than 80% of samples were 
excluded for further analysis to reduce statistical noise. The global mean method was used to 
normalize qPCR results expressed as relative expression (2-ΔCq). The fold change (2-ΔΔCq) method 
was used to compare the relative expression between samples. 
 
MicroRNAs were selected for the next validation phase if they fitted the following 3 
conditions: 
 
1. Significant difference in microRNA relative expression (2 -ΔCq) between 0RS1 and 2RS2; 
2. Significant difference in (2-ΔCq) between 2RS2 and 0RS3; and 
3. A rise and fall pattern in (2-ΔCq). 
 
Validation phase 
Serum samples matched in time with Grade ≥2R biopsies and not used in the discovery phase 
were selected to form the ACR group. The same number of serum samples matched in time with 
0R grade biopsies and not used in the discovery phase were randomly selected to form the no-
ACR group. All selected samples were processed in duplicate. RNA isolation, RT reaction, qPCR 
reaction, and data analysis were carried out as in the discovery phase. In this phase, the qPCR 
reactions were performed using individual primers and the miRCURY LNA miRNA PCR Assay 
Kit (cat: 339306, Qiagen). Cq geometric mean from previously selected reference genes, miR-23b- 
3p, and miR-30c-5p was used to normalize results as in the global mean method (more details in 
Supplementary Material online). 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 8.0 software. Continuous variables 
are presented as mean (95% CI) when normally distributed and as median (interquartile range, <25 
−75>) when non-normally distributed. Categorical data are displayed as count and percentage (n, 
%). The normality distribution was tested by D’Agostino−Pearson and the Shapiro−Wilk test. 
Analysis of differences among 3 groups (discovery phase) was performed using one-way analysis 
of variance with matched data and post-hoc Tukey test (normally distributed) or Friedman’s test 
with Dunn’s correction (non-normally distributed). Unpaired Student’s t-test (normally 
distributed) or Mann−Whitney U-test (non-normally distributed) was performed to compare the 
differences between 2 groups (validation phase). Relative microRNA expression levels (2-ΔCq) 
were log-transformed (base2) before they were analyzed statistically. Pearson’s correlation was 
used to measure the strength of a linear association between 2 variables and was denoted by r. A 
receiver operating characteristic (ROC) curve was generated for selected microRNAs with 
MedCalc software. Areas under the curve (AUCs) and their respective 95% CIs were calculated to 
evaluate the sensitivity and specificity for detecting ACR. Negative predicted value (NPV) and 
positive predicted value (PPV) were calculated for the cut-off with maximum AUC (Youden 
index) and the prevalence for ACR obtained (% EMB ≥ 2R). A two-sided p-value < 0.05 was 




A total of 121 patients were included in the study and their primary heart diseases were dilated 
cardiomyopathy (n = 45; 37%), ischemic cardiomyopathy (n = 44; 36%), hypertrophic 
cardiomyopathy (n  = 13; 11%), congenital cardiomyopathy (n  =  6; 5%), valvular 
cardiomyopathy (n = 5; 4%), and others (n = 8; 7%). The median age of the recipients was 59 
(interquartile range [IQR]: 49-65) years and 82% of them were males. After excluding 4 patients 
(perioperative death), a total of 1,113 EMBs were performed in the remaining 117 patients, with a 
median number of EMBs per patient of 9 (IQR: 8-11). The number of EMBs according to ACR 
International Society of Heart and Lung Transplantation 2005 classification grading criteria was 
0R = 565 (51%), 1R = 461 (41%), 2R = 75 (7%), 3R = 2 (0.2%), and not valid = 10 (0.9%). 
Biopsies where antibody-mediated rejection (AMR) were detected, either isolated AMR (n = 3, 
0.3%) or concomitant with ACR (n = 17, 1.5%), were excluded from the study. 
Table 2 Patient Characteristics at Sampling in 0R, 2R, and 0R During the Discovery Phase 
N=21(0Rs1→2Rs2→0Rs3)  0RS1  2RS2  0RS3  p-value 
Tacrolimus levels, ng/mL 
(95% CI)  
11.2 (9.8−12.7) 9.4 (8.1−10.7)  9.3 (8.2−10.4) allNS. 
Serum creatinine, µmol/L 
(IQR)  
149 (130−170)  133(120−146)  144 (124−164)  all NS. 
Red blood cells, × 1012/L 
(IQR) 
3.46 (3.27−3.66)  3.57 (3.30−3.84)  3.81 (3.59−4.03)  0RS1 vs 0RS3 <0.005 
Blood platelets, × 109/L 
(IQR)  
176 (146−206)  166 (138−193)  173(143−203)  all NS. 
White blood cells, × 109/L 
(IQR)  
7.35 (6.06−8.64) 6.19 (5.02−7.37)  7.05 (5.91−8.20)  all NS. 
Blood lymphocytes, × 109/L 
(95% CI)  
0.82 (0.60−1.05)  1.06 (0.84−1.29)  1.18 (0.98−1.37) 0RS1 vs 2RS2 < 0.05 0RS1 
vs 0RS3 < 0.05 
Blood neutrophils, × 109/L 
(IQR)  
5.99(4.71−7.27)  4.48 (3.50−5.46)  5.17 (4.13−6.20)  all NS. 
CMV viral load    Undetectable  — 
CI, confidence interval; CMV, cytomegalovirus; IQR, interquartile range; NS, not significant 
Discovery phase 
Eleven patients with a 0RS1→2RS2→0RS3 episode and 5 patients with 2 0RS1→2RS2→0RS3 
episodes were included. Thus, 21 0RS1→2RS2→0RS3 episodes and their respective serum samples 
(n = 63) were selected. Patient characteristics at sampling in 0RS1, 2RS2, and 0RS3 are detailed in 
Table 2. The time (days) elapsed from HTx to serum sample collection was 58 (IQR: 35-80) days 
for 0RS1, 102 (IQR: 79-125) days for 2RS2, and 178 (IQR: 139-216) days for 0RS3. It is important 
to note that the 0RS3 corresponds to the first 0R biopsy after the 2R rejection. However, it does not 
have to be necessarily the following biopsy after the 2RS2 because, in most of the patients, before 
the 0RS3 biopsy, there were several 2R or 1R biopsies. The immunosuppression regimen was 
tacrolimus, mycophenolate mofetil, and prednisone in 93.8% of patients and cyclosporine, 
mycophenolate mofetil, and prednisone in 6.2%. Induction therapy with basiliximab was used in 
93.8% of patients and with thymoglobulin in 6.2%. Rejection episodes were treated with a 3-day 
intravenous bolus of methylprednisolone, 250 mg/day (52.4%), 500 mg/day (38.1%), or 1 g/day 
(9.5%). The 3 groups were comparable regarding tacrolimus levels, serum creatine, blood 
platelets, white blood cells, and blood neutrophils. A slight difference, although significant, was 
detected for red blood cell count between samples 0RS1 and 0RS3 and for blood lymphocyte count 
between sample 0RS1 and the other 2 samples. No patient had cytomegalovirus infection at the 
time of sampling (undetectable viral load). 
The mean Cq of the 63 serum samples was 34.71 (95% confidence interval [CI]: 34.47-34.95) 
with no significant differences among the 3 groups (Cq0Rs1 = 34.65 [95% CI: 34.20-35.10], Cq2Rs2 
= 34.69 [95% CI: 34.26-35.13], and Cq0Rs3 = 34.80 [95% CI: 34.36-35.24]). Of the 179 micro-
RNAs analyzed, 31 were not expressed (Cq ≥ 37) in more than 80% of the samples, so they were 
eliminated for further analysis (Supplementary Table S1 online). Of the remaining 148 
microRNAs, only 10 of them were expressed in 100% of the samples: miR-16-5p, miR-23a-3p, 
miR-25-3p, miR-30d-5p, miR-92a-3p, miR-150-5p, miR-223-3p, miR-320a, miR-320b, and miR-
486-5p. After data normalization, Supplementary Figure S1a online shows the 10 microRNAs with 
the highest relative expression (2-ΔCq). MicroRNA fold change (2-ΔΔCq) of the rejection group 
(2RS2) compared with the no rejection group (0RS1) showed 79 (53%) micro-RNAs 
underexpressed and 69 (47%) microRNAs overexpressed, with fold change (2-ΔΔCq) values 
between -1.67 and 1.43 (Supplementary Figure S1b online). 
 
Among the 148 microRNAs analyzed, 4 of them showed a significant difference in relative 
expression (2-ΔCq) between the 0RS1 and 2RS2 groups: miR-181a-5p, miR-339-3p, let-7f-5p, and 
miR-505-3p (Figure 1). However, only miR-181a-5p showed a significant difference in 2-ΔCq 
between 2RS2 and 0RS3 and a rise and fall pattern. 
 
To investigate whether the serum levels of miR-181a-5p could reflect blood lymphocyte count, 
a correlation was performed between both variables. There was no statistical correlation between 
miR-181a-5p and blood lymphocyte count. The Spearman’s r = 0.170 (95% CI: -0.096 to 0.412) 
demonstrated that miR-181a-5p expression is independent of blood lymphocyte count. Therefore, 
miR-181a-5p was chosen to be evaluated in the next validation phase. 
Validation phase 
For the ACR group, 45 serum samples were found, 44 EMB = 2R and 1 EMB = 3R. Therefore, 
the no-ACR group was completed with 45 random serum samples from patients with EMB = 0R. 
The time (days) elapsed from HTx to serum sample collection was 51 (IQR: 26-99) days for the 
ACR group and 100 (IQR: 44-170) days for the no-ACR group. Patients’ characteristics are 
detailed in Table 3. The immunosuppression regimen was tacrolimus, mycophenolate mofetil, and 
prednisone in 93% of patients; cyclosporine, azathioprine, and prednisone in 4.7%; and 
cyclosporine, mycophenolate mofetil, and prednisone in 2.3%. Induction therapy with basiliximab 
was used in 93.5% of patients and with thymoglobulin in 6.5%. Rejection episodes were treated 
with a 3-day intravenous bolus of methylprednisolone: 250 mg/day (51.5%), 500 mg/day (36.4%), 
or 1 g/day (6.1%).There were no significant differences between both groups. miR-181a-5p was 
significantly overexpressed (p <0.0001) in the ACR group compared with the no-ACR group. 
Median miR-181a-5p expression levels were 0.465 (IQR:0.338-0.541), and 0.254 (IQR: 0.155-
0.341) in the ACR and no-ACR groups, respectively (Figure 2). Sensitivity analysis(ROC curve) 
showed that for a miR-181a-5p cut-off of 2-ΔCq > 0.33), an AUC of 0.804 (95% CI: 0.707-0.880) 
was obtained (p < 0.0001) (Figure 2, Supplementary Table S2 online). The sensitivity and the 
specificity for this cut-off were 78% and 76%, respectively. For the prevalence obtained of 7% in 
this study (EMB ≥ 2R), NPV and PPV were 98% and 20%, respectively. 
  
Discussion 
MicroRNAs have been postulated as new potential noninvasive biomarker candidates for heart 
transplant rejection.12−18 In this study, after evaluating 179 serum micro-RNAs in the initial 
discovery phase, the circulating miR-181a-5p showed a rise and fall pattern that make it a potential 
non-invasive biomarker to detect ACR in HTx. These results were confirmed in the discovery 
phased using a new cohort of patients with ACR and where miR-181a-5p was found to be 
overexpressed compared with those with no rejection. Thus, as a non-invasive biomarker for ACR 
detection in HTx, miR-181a-5p showed promising results, with an AUC of 0.804 (95% CI: 0.707-
0.880) and a sensitivity and specificity of 78% and 76%, respectively. 
 
To our knowledge, 12 microRNAs has been previously described12,13,15−17 associated with 
cardiac graft rejection (Table 1). In this study, we tested 10 of these microRNAs (miR-101-3p, 
miR-142-3p, miR-144-3p, miR-326, miR-339-3p, miR-424-5p, miR-92a, miR-155, miR-29, and 
miR-27-3p) and none of them presented a rise and fall pattern expression during the rejection 
event in the cohort studied. The other 2 microRNAs previously described, miR-10a and miR-31, 
only were associated with ACR in 1 out of the 5 studies previously published.13 This lack of 
reproducibility between the studies could be in part explained by the different designs, the poor 
standardization, and the use of several normalization methods of the data. In this study, the latest 
recommendations to standardize the experiments were followed.20 First, the longitudinal design of 
the experiment in the discovery phase, where the same patient is studied before, during, and after 
the ACR episode, together with an adequate sample size, gave the study a reliable statistical 
power. Second, in microRNA expression profile experiments, provided the normalization method 
is correct, there should be as many overexpressed as underexpressed microRNAs. In the discovery 
phase of this study, after global mean normalization, microRNAs under- and overexpressed were 
fairly similar, 50% each (Supplementary Figure S1b online). Finally, in the validation phase, the 
normalization of RT-qPCR data was performed first, using 2 endogenous reference genes (miR-
23b-3p and miR-30c-5p) and the geometric mean method. 
 
Sukma Dewi et al.12 is the only study where samples before, during, and after cellular rejection 
were used. Significantly increased levels of miR-326 and miR-142-3p during ACR and an AUC of 
0.86 and 0.80, respectively, were described.12 This was a small pilot study with only 10 patients 
included, and later the same authors increased the cohort (ACR = 26).17 However, the most 
promising micro-RNA in the previous study,12 miR-326, in the new approach presented a lower 
AUC, 0.69 versus 0.86. On the other hand, in the study of Duong van Huyen et al.,13 4 micro-
RNAs (miR-10a, miR-31, miR-92a, and miR-155) differentially expressed in rejection patients 
with almost perfect ROC curves (AUC ≈ 1) were identified. However, the cohort studied was 
formed by 14 ACR and 17 AMR patients, and thus the results obtained were not exclusively of 
cellular rejection after HTx. Thus, although the number of microRNA studies for the detection of 
ACR is small, all these results suggest that microRNAs could be candidates as biomarkers. 
 
Currently, there is only 1 non-invasive test approved by FDA for monitoring ACR, Allomap 
(CareDx).6,23,24 Allomap, a gene expression profiling test in blood leukocytes, showed an AUC of 
0.70, lower than the AUC here obtained for miR-181a-5p (Table 4). Because the estimation of 
NPVs and PPVs varies based on the disease prevalence of the screened population, an estimated 
prevalence of 5% was established to compare results (Table 4). Our results showed that miR-181a-
5p presented an NPV of 98.5%, whereas the NPV for Allomap was lower (NPV = 95.7%). Thus, 
the results here obtained for miR-181a-5p are similar to or even better than, in terms of AUC and 
NPV, those of Allomap and other biomarkers under investigation (T regulatory cells to endothelial 
progenitor cells, troponin I, and donor-derived cell-free DNA) (Table 4).7,25,26 So, although our 
results were obtained analyzing 61 EMB blood samples from patients with Grade ≥2R EMB from 
only 1 hospital and under ideal conditions (no EMB = 1R were included), our data led us to 
hypothesize that miR-181a-5p may become a useful biomarker for monitoring ACR, using an 
inexpensive, robust, and feasible technology, which may lead to a reduction in the number of 
EMBs. 
 
Figure 1. Significant differentially expressed microRNAs during ACR episode. Data are presented as median 
relative expression (2-ΔCq) (bars) and interquartile range (whiskers). All adjusted p-values were obtained by one-way 
ANOVA and post-hoc Tukey test. NS if  p ≥ 0.05,× if p < 0.05, and ** if p < 0.005. ACR, acute cellular rejection; 
ANOVA, analysis of variance; NS, not significant. 
Moreover, it has been described that the miR-181 family regulates T- and B-cell 
development,27−30 and this function could explain this important role in ACR. Li et al.28 
demonstrated that miR-181a modulates the sensitivity of T cells to foreign and endogenous 
antigens through T-cell receptor signaling. It was also demonstrated that miR-181a overexpression 
increases the number of B cells.27−29 In HTx, during an ACR episode, T cells mediate an 
inflammatory response that leads to infiltration and lesion of the myocardium by mononuclear 
cells (activated macrophages, T cells, and B cells). The high grade of evidence that miR-181a is 
strongly involved in this alloimmune response makes our results very plausible from the biological 
point of view. This biological evidence supports the idea that miR-181a might be a promising 
biomarker not only for ACR detection but also for microRNA-based therapies and monitoring the 
immunosuppressive treatment. 
Table 3. Validation Phase Patients’ Baseline Characteristics 
Patient characteristics  No-R  
 n = 45 
 ACR 
 n = 45  
p-value 
Males  36 (80%)  36 (80%)  — 
Age at HTx  60 (44-65) 55 (49-63)  NS. 
Tacrolimus levels, ng/mL (95% CI) 11.1 (9.9-12.2) 10.6 (9.4-11.7)  NS. 
Serum creatinine, µmol/L (IQR) 110 (88-133)  98 (77-133)  NS. 
Red blood cells, × 1012/L (IQR) 3.71 (3.52-3.89)  3.60 (3.48-3.73) NS. 
Blood platelets, × 109/L (IQR) 223 (199-247)  216 (183-249) NS. 
White blood cells, × 109/L (IQR) 6.19 (5.35-7.92)  6.68 (4.58-9.17)  NS. 
Blood lymphocytes, × 109/L (95% CI) 1.14 (0.96-1.31)  1.20 (1.03-1.37)  NS. 
Blood neutrophils,  × 109/L (IQR) 4.52 (3.43-5.93)  4.69 (3.06-7.17)  NS. 
ACR, acute cellular rejection; CI, confidence interval; HTx, heart transplantation; IQR, interquartile  





Figure 2. miR-181a-5p expression in validation phase (a) miR-181a-5p relative expression (2-ΔCq) in no-ACR and ACR 
groups presented as median (bars) and interquartile range (whiskers); **** if p < 0.0001. (b) ROC curve for evaluation of 







Our study has several limitations and, although miR-181a-5p seems to be a promising ACR 
biomarker, it is a long pathway until it can reach its clinical application. First, because of the 
design of the study, the diagnostic accuracy of miR-181a-5p should be assessed in a larger 
multicenter prospective cohort with randomly selected patients. It would also be necessary to 
assess miR-181a-5p in patients with Grade 1R ACR to study if miR-181a-5p correlates with the 
severity of the rejection episode. Moreover, the effect of different treatments on the levels of miR-
181a-5p post-rejection should also be analyzed. Finally, although we performed an ambitious 
study where 179 microRNAs were studied, other microRNAs not included may also have a role in 
ACR. 



























































Troponin I  Patel et 
al.26  
2014  383  19 EMB ≥ 2R 
8 AMR  
5 Mixed  
3 HC 
>1  0.82 
(0.76−0.88)  
94  60  99.5  11 
cfdDNA  De 
Vlaminck 
et al.7  
2014  185  24 EMB ≥ 2R 
or AMR 
>1  0.83  58  93  97.7  30.4 
Treg/EPC  Choi et 
al.25  




—  —  —  — 
miR-181a-5p  This 
study  
 
—  45  45 EMB ≥ 2R  1−6  0.80 
(0.71−0.88)  
78  76  98.5  14.6 
ACR, acute cellular rejection; AMR, antibody-mediated rejection; AUC, area under the curve; cfdDNA, cell-free donor-
derived DNA; EMB, endomyocardial biopsy; HC, hemodynamic compromise; HTx, heart transplantation; NPV, negative 
predicted value; PPV, positive predicted value; S, sensitivity; SP, specificity; Treg/EPC, T regulatory cells to endothelial 
progenitor cells.  
aNPV and PPV calculated for an arbitrary prevalence of 5% for acute rejection. 
Conclusions 
miR-185a-5p in serum is a candidate as a non-invasive ACR biomarker with an AUC of 0.80 
and an NPV of 98%. Thus, this biomarker could reduce the need for EMBs and the associated 
risks and costs of this invasive procedure. 
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